GHRP-2 vs GHRP-6

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 18 references

GHRP-2 and GHRP-6 are different molecules: each is a synthetic six-residue peptide, and they differ in composition, including how many of their residues are D-configured.

Structure at a glance

GHRP-2 and GHRP-6 are both 6 residues long. Filled: the 2 positions where the residues differ.

GHRP-2

NH2

GHRP-6

NH2

NH2: C-terminal amide. A raised D marks a D-amino acid. 2Nal: 2-naphthylalanine. Codes are three-letter amino acid codes.

Chain length
GHRP-26 residues
GHRP-66 residues
Molecular weight
GHRP-2817.99 g/mol
GHRP-6873.01 g/mol

Drawn from the product database. Each measure's bars share one scale.

GHRP-2 vs GHRP-6, compared
What it isA synthetic six-residue peptide with a free N-terminal amine and a C-terminal amide.A synthetic six-residue peptide with a free N-terminal amine and a C-terminal amide.
How they relateDifferent molecules. GHRP-2 is a synthetic hexapeptide in which three of the six residues are D-configured. GHRP-6 is a synthetic hexapeptide in which two of the six residues are D-configured.
CAS number158861-67-787616-84-0
Molecular formulaC45H55N9O6C46H56N12O6
Molecular weight817.99 g/mol873.01 g/mol
SequenceD-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Evidence baseHuman data on GHRP-2 are narrow, and no registered study tests it as a treatment.[1]More than 80 published human studies, mostly single-dose; repeated use lasted a week at most.[14] Published controlled trials with a clinical outcome gave it with epidermal growth factor; the larger missed its primary endpoint.[15]
Regulatory statusThe FDA has not approved GHRP-2. Pralmorelin hydrochloride is approved in Japan as a diagnostic agent.[17]The FDA has not approved GHRP-6 for human use.
Compared head-to-head?Yes: a 1998 study tested GHRP-2 and GHRP-6 in conscious swine.[3] Another 1998 study tested both in human pituitary and hypothalamic membranes.[4] Further comparisons found in PubMed (searched October 2026).[5]
Handling differenceNeither contains cysteine or methionine. GHRP-2 carries one tryptophan and GHRP-6 two, and tryptophan can oxidize.

How GHRP-2 and GHRP-6 differ

GHRP-2 and GHRP-6 are different molecules. Both are synthetic six-residue peptides with a free N-terminal amine and a C-terminal amide. Their compositions differ. Three of GHRP-2's six residues are D-configured, it carries one tryptophan, and one of its residues, 2-naphthylalanine, does not occur in proteins. Two of GHRP-6's six residues are D-configured, and it carries two tryptophans.

A small human study often cited for GHRP-6 tested GHRP-2 and a third peptide.[6] GHRP-6 appears in it only in the introduction and was not tested.[6] No finding from that study was obtained with GHRP-6. FDA's review cites reports of increased insulin requirement, infection, pancreatitis and deaths among critically ill study subjects given GHRP-2.[7] Reports like these cannot show that GHRP-2 caused the events or how often they occur.

More than 80 published studies have given GHRP-6 to people, most of them single-dose tests; published studies of repeated use lasted a week at most.[14] The published controlled trials with a clinical outcome gave it together with epidermal growth factor, and the larger one missed its primary endpoint.[15] ClinicalTrials.gov lists no trial of GHRP-6.[2] The Cuban public registry lists at least seven, and no results have been located for four of them.[16] An author of the 1990 human study of GHRP-6 held an inventor interest.[8] The literature reviewed for GHRP-6 reports no serious safety finding from its human studies.

Neither peptide contains cysteine, methionine, asparagine, glutamine or aspartate. Each carries a tryptophan indole, which air, light and trace metals can oxidize. Heated in solution, GHRP-6 degraded by C-terminal deamidation, hydrolysis and head-to-tail cyclization, and oxidized tryptophan forms were minor.[18] In GHRP-6, the histidine coordinates transition metals, and trace metal contamination promotes tryptophan oxidation. Each is cationic and carries aromatic rings, so each can adsorb to surfaces both electrostatically and hydrophobically. In GHRP-2, those rings include the fused bicyclic naphthalene of its 2-naphthylalanine. In each, mass spectrometry cannot verify the configuration of the D-residues, since a D-residue and its L-form are identical in mass.

The FDA has not approved either GHRP-2 or GHRP-6. Pralmorelin hydrochloride, a salt of GHRP-2, is approved in Japan as a diagnostic agent.[17] Pralmorelin hydrochloride is the active ingredient of a diagnostic medicine sold there under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.

Have GHRP-2 and GHRP-6 been compared directly?

A 1998 study tested GHRP-2 and GHRP-6 in conscious swine.[3] Results are reported for each compound in that model. Five studies in cells or tissue tested GHRP-2 and GHRP-6 in the same system. Two used human material: pituitary and hypothalamic membranes (1998)[4] and cell cultures from pituitary tumors (1996).[9] Three used animal pituitary cells: rat (1997),[10] sheep and rat (1996)[11] and sheep (1997).[12] Results are reported for each compound in each assay. A 2013 study tested both in mice.[13] Results are reported for each compound in that model.

Read more on each compound

Frequently Asked Questions

Is GHRP-2 the same as GHRP-6?+

GHRP-2 and GHRP-6 are different molecules, though each is a synthetic six-residue peptide. Three of GHRP-2's residues are D-configured, and one, 2-naphthylalanine, does not occur in proteins. Two of GHRP-6's residues are D-configured, and it carries two tryptophans.

Does research on GHRP-2 apply to GHRP-6?+

A small human study often cited for GHRP-6 tested GHRP-2 and a third peptide, and GHRP-6 was not tested in it. No finding from that study was obtained with GHRP-6.

References

  1. 1
    Registry searches, 16 October 2026: ClinicalTrials.gov, the EU Clinical Trials Register, ANZCTR, and Japan's jRCT and UMIN-CTR. No registered study tests GHRP-2 as a treatment; registered studies use it as a diagnostic test or in anti-doping research.
  2. 2
    ClinicalTrials.gov v2 API, per-compound queries by intervention and general term, 27 August 2026. GHRP-6 returns zero registered studies, as it still did on 16 October 2026.
  3. 3
    Raun K, et al. Eur J Endocrinol 1998. PMID 9849822. DOI: 10.1530/eje.0.1390552.
  4. 4
    Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, Nilsson MH, Deghenghi R, Ong H, Ghigo E. J Endocrinol. 1998;157(1):99-106. PMID 9614363.
  5. 5

    PubMed search, 3 October 2026 (records to 2 October 2026)

    40 records, including the 7 direct comparisons described above.

    Exact query (NCBI E-utilities): ("GHRP-2"[tiab] OR "GHRP 2"[tiab] OR "GHRP2"[tiab] OR "pralmorelin"[tiab] OR "growth hormone-releasing peptide-2"[tiab] OR "growth hormone releasing peptide-2"[tiab] OR "growth hormone releasing peptide 2"[tiab]) AND ("GHRP-6"[tiab] OR "GHRP 6"[tiab] OR "GHRP6"[tiab] OR "growth hormone-releasing peptide-6"[tiab] OR "growth hormone releasing peptide-6"[tiab] OR "growth hormone releasing peptide 6"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  6. 6
    Arvat E, et al. Peptides 1997. PMID 9285939. DOI: 10.1016/s0196-9781(97)00016-8. GHRP-2 and hexarelin only; GHRP-6 was not administered.
  7. 7
    US Food and Drug Administration. Web page, retrieved 4 October 2026. fda.gov
  8. 8
    Human study, 1990. PMID 2108187.
  9. 9
    Human cell study, 1996. PMID 8721987.
  10. 10
    Cheng J, Wu TJ, Butler B, Cheng K. Life Sci. 1997;60(16):1385-1392. PMID 9096259.
  11. 11
    Animal cell study, 1996. PMID 8699133.
  12. 12
    Wu D, Clarke IJ, Chen C. J Endocrinol. 1997;154(2):219-230. PMID 9291832.
  13. 13
    Zeng P, Chen JX, Yang B, Zhi X, Guo FX, Sun ML, Wang JL, Wei J. Peptides. 2013;50:42-49. PMID 24113541.
  14. 14
    PubMed searches via NCBI E-utilities, run 16 October 2026, for GHRP-6 under its name variants and its sequence. Limited to clinical trial and clinical study publication types: 56 records, 38 of them giving GHRP-6 to people. Limited to humans: 322 records, 97 giving it to people. Some describe the same participants.
  15. 15
    Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, et al. J Clin Neurosci. 2026;152:112195. doi:10.1016/j.jocn.2026.112195. PMID 42462342. Randomized, open-label phase III trial; primary endpoint not met.
  16. 16
    WHO International Clinical Trials Registry Platform search portal, searches run 16 October 2026: at least seven interventional trials of the same peptide in the Cuban Public Registry of Clinical Trials, registered from 2010 to 2026 under its name and under its sponsor's code. No results were located for four of them.
  17. 17
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Approval of pralmorelin hydrochloride for injection as a diagnostic agent on 22 October 2004, recorded in PMDA's 2014 re-examination report; current package insert revised July 2025. In Japanese. pmda.go.jp
  18. 18
    Santana H, et al. J Pharm Biomed Anal 2021. PMID 33272786. DOI: 10.1016/j.jpba.2020.113776.
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

GHRP-6 vs Ipamorelin

GHRP-6 and Ipamorelin are different molecules: GHRP-6 is a synthetic six-residue peptide; Ipamorelin is a synthetic five-residue peptide.

Read Comparison
Comparison

AOD-9604 vs HGH Fragment 176-191

AOD-9604 and HGH Fragment 176-191 are 16-residue peptides from the C-terminal end of human growth hormone that differ at one position.

Read Comparison
Comparison

AOD-9604 vs Tesamorelin

AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.

Read Comparison